Compare Global X Copper Miners ETF (COPX) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Eli Lilly And Co — how do they compare? Global X Copper Miners ETF trades at $84.47 (market cap $7.10B), while Eli Lilly And Co trades at $1,164.28 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 146.5× Global X Copper Miners ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Eli Lilly And Co for 93 Days on average.
| COPX | LLY | |
|---|---|---|
Market Cap | $7.10B | $1.04T |
Volume | 2,871,128 | 3,064,878 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $1.28K |
52-Week Low | $57.43 | $799.57 |
Typical Hold Time | 50 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) is trading at $83.58, down 3.13% with a bearish technical signal. The ETF faces selling pressure with 15 sell signals versus 2 buy signals across technical indicators. Copper fundamentals remain strong with prices near all-time highs above $6.85 per pound, driven by AI infrastructure demand and supply constraints. Recent news highlights copper's critical role in electrification and AI infrastructure, though technical indicators suggest near-term weakness.
The long-term copper thesis remains compelling due to structural supply deficits and AI-driven demand growth. However, near-term risks include potential Federal Reserve policy impacts and mining equity underperformance relative to copper prices. The ETF offers operational leverage to copper prices but faces volatility from global surplus projections and macroeconomic factors.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
